RxDoctor Payments Data

Ramaswami Sundar, MD

Neurology · Brooklyn, NYNPI 1568404275

Payments from drug & device makers

$1,782in general payments, 2019–2025

Across 76 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$339
  • SK Life Science, Inc.$238
  • Octapharma USA, Inc.$226
  • AbbVie$180
  • Neurocrine Biosciences, Inc.$152
  • Pfizer$127
  • plus $521 from 13 others

What the payments were for

  • Food & beverage$1,782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,782 in reported general payments places this provider in the 50th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$9,203
Medicare patients
52
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$108,709
Avonex (4 Pack)Interferon Beta-1a13$100,577
NuedextaDextromethorphan Hbr/Quinidine11$17,032
Lamictal OdtLamotrigine12$13,215
NamzaricMemantine Hcl/Donepezil Hcl12$12,359
Lacosamide34$3,179
Levetiracetam57$2,626
Memantine Hcl60$1,506
Donepezil Hcl139$1,457
Gabapentin140$1,415
Carbamazepine13$1,071
Celecoxib14$845
Carbidopa-LevodopaCarbidopa/Levodopa19$551
Pregabalin31$532
Phenobarbital14$497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$152$108,70913 claims
BiogenAvonex (4 Pack)$49$100,57713 claims
AbbVieNamzaric$180$12,35912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,623 neurology providers in New York.

Other neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →